Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 2 |
2016 | 1 |
2018 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5. doi: 10.1016/j.diagmicrobio.2015.04.012. Epub 2015 May 1.
Diagn Microbiol Infect Dis. 2015.
PMID: 26003469
Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP, Kuti JL.
Pettit RS, et al.
J Antimicrob Chemother. 2016 Jan;71(1):189-95. doi: 10.1093/jac/dkv289. Epub 2015 Sep 27.
J Antimicrob Chemother. 2016.
PMID: 26416780
Item in Clipboard
Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.
Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.
Kuti JL, et al.
Diagn Microbiol Infect Dis. 2018 Jul;91(3):294-297. doi: 10.1016/j.diagmicrobio.2018.01.020. Epub 2018 Feb 24.
Diagn Microbiol Infect Dis. 2018.
PMID: 29661528
Clinical Trial.
Item in Clipboard
Cite
Cite